Want to see KR:170900 full AI Analyst Report?
Top Page
Dong-A ST Co., Ltd.
(170900)
Select Model
Select Model
Rating:46Neutral
Price Target:
$34,202.00
Action:N/A
Date:10/28/26
The score is held back primarily by weak earnings quality and persistent cash burn (negative OCF/FCF), despite steady revenue growth and solid gross margins. Technicals add pressure due to a downtrend versus key moving averages and negative MACD. Valuation is mixed: a modest dividend yield helps, but a negative P/E reflects unstable profitability.
Positive Factors
Revenue Growth and Gross Margin
Steady revenue expansion combined with a solid gross margin indicates that Dong-A ST retains meaningful economic value in its pharmaceutical portfolio. This provides a foundation for operating leverage and continued investment in research, commercialization, and selected overseas growth.
Negative Factors
Persistent Cash Consumption
Negative operating and free cash flow indicate that reported business activity is not yet converting reliably into cash. Continued cash consumption can increase reliance on funding or balance-sheet capacity, limiting flexibility to invest, absorb setbacks, or support long-term growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Gross Margin
Steady revenue expansion combined with a solid gross margin indicates that Dong-A ST retains meaningful economic value in its pharmaceutical portfolio. This provides a foundation for operating leverage and continued investment in research, commercialization, and selected overseas growth.
Read all positive factors
Dong-A ST Co., Ltd. (170900) vs. SPDR S&P 500 ETF (SPY)
Market Cap
₩332.73B
Dividend Yield2.01%
Average Volume (3M)6.93K
Price to Earnings (P/E)―
Beta (1Y)0.03
Revenue Growth15.38%
EPS GrowthN/A
CountryKR
Employees1,685
SectorGeneral
Sector StrengthN/A
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-611.41
Shares Outstanding9,727,881
10 Day Avg. Volume7,860
30 Day Avg. Volume6,930
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.78
Price to Sales (P/S)0.62
P/FCF Ratio-49.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)3,488.75
Revenue Forecast (FY)₩853.52B
Dong-A ST Co., Ltd. Business Overview & Revenue Model
Company Description
Dong-A ST Co., Ltd. is a global enterprise focused on the research, development, production, and commercialization of a broad spectrum of pharmaceutical products and medical devices. The company's diverse portfolio of ethical drugs targets various...
Dong-A ST Co., Ltd. Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
56
Neutral
Cash Flow
32
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 860.94B | 808.79B | 697.87B | 663.98B | 635.39B | 593.23B |
| Gross Profit | 375.93B | 356.50B | 340.20B | 322.21B | 315.39B | 293.88B |
| EBITDA | -36.34B | 33.45B | 28.99B | 45.07B | 49.42B | 35.51B |
| Net Income | 2.92B | -28.59B | -1.22B | 11.12B | 13.55B | 12.82B |
Balance Sheet | ||||||
| Total Assets | 1.35T | 1.41T | 1.39T | 1.26T | 1.16T | 1.12T |
| Cash, Cash Equivalents and Short-Term Investments | 213.24B | 291.69B | 301.08B | 286.42B | 289.32B | 304.49B |
| Total Debt | 487.71B | 537.06B | 495.66B | 406.71B | 312.18B | 300.58B |
| Total Liabilities | 680.60B | 740.40B | 682.93B | 581.11B | 467.61B | 459.61B |
| Stockholders Equity | 647.35B | 642.71B | 670.29B | 657.37B | 671.58B | 656.38B |
Cash Flow | ||||||
| Free Cash Flow | -30.19B | -10.10B | -43.88B | -38.65B | -35.97B | -31.07B |
| Operating Cash Flow | -6.70B | 12.04B | -11.79B | 3.37B | 32.89B | 49.37B |
| Investing Cash Flow | 32.23B | -64.08B | -111.18B | -109.42B | 49.41B | -85.82B |
| Financing Cash Flow | -11.26B | 35.65B | 86.96B | 54.59B | -8.90B | 81.78B |
Dong-A ST Co., Ltd. Technical Analysis
Negative
―
Price Trends
36007.00
Negative
35904.00
Negative
40949.56
Negative
Market Momentum
-262.64
Negative
47.59
Neutral
36.19
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:170900, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 34865.00, equal to the 50-day MA of 36007.00, and equal to the 200-day MA of 40949.56, indicating a neutral trend. The MACD of -262.64 indicates Negative momentum. The RSI at 47.59 is Neutral, neither overbought nor oversold. The STOCH value of 36.19 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:170900.
Dong-A ST Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | ₩560.29B | 5.53 | ― | 2.80% | 10.50% | 96.29% | |
61 Neutral | ₩1.15T | 5.90 | ― | 0.60% | 9.87% | 160.28% | |
60 Neutral | ₩404.42B | 8.96 | ― | 1.56% | -0.65% | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
51 Neutral | ₩435.39B | -884.82 | ― | 0.08% | 6.21% | 95.65% | |
50 Neutral | ₩369.99B | 64.89 | ― | 3.33% | 22.17% | -38.54% | |
46 Neutral | ₩332.73B | -56.26 | ― | 2.01% | 15.38% | ― |
* General Sector Average
KR:170900
Dong-A ST Co., Ltd.
34,900.00
-8,968.36
-20.44%
KR:001060
JW Pharmaceutical Corporation
23,200.00
191.16
0.83%
KR:003000
Bukwang Pharmaceutical Co., Ltd.
3,750.00
95.20
2.60%
KR:019170
Shinpoong Pharmaceutical Co., Ltd.
8,460.00
-5,550.00
-39.61%
KR:069620
Daewoong Pharmaceutical Co., Ltd.
99,900.00
-39,418.48
-28.29%
KR:249420
Ildong Pharmaceutical Co., Ltd.
12,790.00
-10,206.94
-44.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.